Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
130M
-
Number of holders
-
194
-
Total 13F shares, excl. options
-
100M
-
Shares change
-
+16M
-
Total reported value, excl. options
-
$4.99B
-
Value change
-
+$866M
-
Put/Call ratio
-
4.14
-
Number of buys
-
141
-
Number of sells
-
-63
-
Price
-
$49.94
Significant Holders of Vaxcyte, Inc. - COMMON STOCK (PCVX) as of Q2 2023
232 filings reported holding PCVX - Vaxcyte, Inc. - COMMON STOCK as of Q2 2023.
Vaxcyte, Inc. - COMMON STOCK (PCVX) has 194 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 100M shares
of 130M outstanding shares and own 76.96% of the company stock.
Largest 10 shareholders include FMR LLC (14.1M shares), VANGUARD GROUP INC (8.24M shares), RA CAPITAL MANAGEMENT, L.P. (7.89M shares), BlackRock Inc. (7.07M shares), JANUS HENDERSON GROUP PLC (7.06M shares), WELLINGTON MANAGEMENT GROUP LLP (4.43M shares), Capital Research Global Investors (3.36M shares), STATE STREET CORP (3.16M shares), FRED ALGER MANAGEMENT, LLC (2.37M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (2.19M shares).
This table shows the top 194 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.